SYRS

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) is a biopharmaceutical company founded in 2011 and headquartered in Cambridge, Massachusetts. The company was initially incorporated as LS22, Inc. before changing its name to Syros Pharmaceuticals in August 2012 and went public in June 2016. Syros focuses on developing treatments for blood cancers and rare genetic diseases by targeting gene control mechanisms. The company is currently in late-stage clinical development with its lead drug candidate approaching pivotal trial results, positioning itself as a potential commercial-stage biotechnology company.